-- Dr. Reddy's Laboratories (RDY) said Wednesday it received a Notice of Compliance from Health Canada to market its generic semaglutide injection.
The regulatory clearance makes the pharmaceutical manufacturer the first company to obtain approval for the type 2 diabetes treatment in the country, the company said.
The authorization covers the 2 mg and 4 mg pen dosages and was granted ahead of the agency's target review date, it said.
Shares of the company were down 1.9% in Wednesday trading.
Price: $13.77, Change: $-0.26, Percent Change: -1.89%